Special Issue "Artemisinin: Against Malaria, Cancer and Viruses"
Deadline for manuscript submissions: 31 March 2017
Prof. Dr. Svetlana B. Tsogoeva
Institut für Organische Chemie, Friedrich-Alexander Universität Erlangen-Nürnberg Henkestrasse 42, 91054 Erlangen, Germany
Website | E-Mail
Interests: asymmetric organocatalysis; organo-autocatalysis; asymmetric oxidations with non-heme iron complexes; synthesis of artemisinin-derived hybrids for medicinal chemistry
The natural 1,2,4 trioxane sesquiterpene artemisinin, isolated from the Chinese medicinal plant Artemisia annua L. (sweet wormwood) in 1972 by Youyou Tu (Nobel Prize, 2015), has proven to be a versatile antimalarial. In order to improve the pharmacological properties of artemisinin, several semisynthetic derivatives were developed: dihydroartemisinin, artesunic acid, and artemether. All three artemisinin derivatives proved to be highly active against malaria parasites and different cancer cell lines and also against viruses. In addition to the high safety of artemisinin and its derivatives, a high therapeutic tolerance, effectivity and a unique mode of action can be mentioned as the advantages of these compounds. Although the mechanism of action of artemisinin is still not completely understood, it is generally accepted that the endoperoxide linkage within the 1,2,4 trioxane system is essential for its activities. Generation of reactive oxygen species (ROS) and carbon-centered radicals are widely accepted as key intermediates responsible for the antimalarial and anticancer activities of artemisinin and its derivatives. In case of malaria, a disruption of the cellular redox cycling, an inhibition of a calcium-ATPase (SERCA, pFATP6), as well as a depolarization of the mitochondrial potential is discussed further. The advantage of artemisinin and its semi-synthetic analogue artesunic acid as anticancer agents lies not only in their potency as toxic agents to cancer cells, but also in their low toxicity to normal cells.
Over the past decade, a great deal of attention has been paid to the synthesis of new artemisinin derivatives and of a wide variety of atemisinin-derived dimers and hybrids as lead compounds of interest. These new molecular structures demonstrate improved properties compared to their parent compounds (e.g., circumventing multidrug resistance and low bioavailability), making the dimerization/hybridisation concept highly compelling for development of efficient antimalarial, anticancer and antiviral drugs.
The present Special Issue intends to highlight the past and present role of artemisinin and different types of artemisinin-derived compounds for the development of new efficient therapeutics for the treatment of malaria, cancer, and viruses and will consider the future prospects of artemisinin for drug discovery.
Prof. Dr. Svetlana B. Tsogoeva
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- medicinal chemistry
- artemisinin’s mode of action
- artemisinin-derived hybrids/dimers